Cedar Mountain Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Cedar Mountain Advisors’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-18	Closed	-$724	–	1180
2026 Q1	$724	Buy	+18	New	+$388	﹤0.01%	965

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Cedar Mountain Advisors's APLS Position: Q2 2026 in Review

Cedar Mountain Advisors sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 18 shares — an estimated $724 sold.

Cedar Mountain Advisors first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $724 in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Cedar Mountain Advisors reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Cedar Mountain Advisors sold 18 Apellis Pharmaceuticals shares in Q2 2026, an estimated $724.
Cedar Mountain Advisors first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Cedar Mountain Advisors's Apellis Pharmaceuticals position peaked at $724 in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.